Patents by Inventor Richard M. Cooper

Richard M. Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240182396
    Abstract: The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.
    Type: Application
    Filed: August 16, 2023
    Publication date: June 6, 2024
    Inventors: Richard Copp, Mohamed Abdelnasser, Christopher M. Cimarusti, Jonathan Lane, Michael Barkman, Rasidul Amin, Arthur John Cooper, Damodaragounder Gopal, Philipp Selig
  • Patent number: 11987548
    Abstract: The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14, 14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: May 21, 2024
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Richard Copp, Mohamed Abdelnasser, Christopher M. Cimarusti, Jonathan Lane, Michael Barkman, Rasidul Amin, Arthur John Cooper, Damodaragounder Gopal, Philipp Selig
  • Patent number: 11926584
    Abstract: The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: March 12, 2024
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Richard Copp, Mohamed Abdelnasser, Christopher M. Cimarusti, Jonathan Lane, Michael Barkman, Rasidul Amin, Arthur John Cooper, Damodaragounder Gopal, Philipp Selig
  • Patent number: 9887906
    Abstract: A method of establishing a first network connection of a wired network with a customer premise equipment (CPE) installed at a customer premise (CP). The method monitors the first network connection and detects an outage of the first network connection. The method provides an option of using a second network connection of a wireless network, for delivery of services during the first outage of the first network connection. The method receives a response, and switches the delivery of services, via a machine to machine (M2M) interface in the CPE, to the second network connection.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: February 6, 2018
    Assignee: Verizon Patent and Licensing Inc.
    Inventors: Jan Marcel Rijnders, Ashley Dickenson, Michelle L. Opitz, Eric Duane Culpepper, Anthony S. Tutwiler, Richard M. Cooper, Thomas Edward Sibrizzi, Christopher A. Kimm
  • Publication number: 20160080248
    Abstract: A method of establishing a first network connection of a wired network with a customer premise equipment (CPE) installed at a customer premise (CP). The method monitors the first network connection and detects an outage of the first network connection. The method provides an option of using a second network connection of a wireless network, for delivery of services during the first outage of the first network connection. The method receives a response, and switches the delivery of services, via a machine to machine (M2M) interface in the CPE, to the second network connection.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 17, 2016
    Inventors: Jan Marcel Rijnders, Ashley Dickenson, Michelle L. Opitz, Eric Duane Culpepper, Anthony S. Tutwiler, Richard M. Cooper, Thomas Edward Sibrizzi, Christopher A. Kimm
  • Patent number: 4987077
    Abstract: The invention provides an enzyme preparation comprising at least one protease derived from an entomopathogenic fungus of one of the following genera:Metarhizium, Beauvaria, Verticillium, and Aschersonia, and characterized by the following properties:(a) substantially not activity against hide protein azure, locust cuticel and elastin;(b) specificity for Bz-Phe-Val-ARg-NA;(c) not inhibited by soybean trypsin inhibitor.
    Type: Grant
    Filed: May 24, 1988
    Date of Patent: January 22, 1991
    Assignee: Agricultural Genetics Company Limited
    Inventors: Anthony K. Charnley, Richard M. Cooper, Raymond J. St. Leger